162 related articles for article (PubMed ID: 38081125)
21. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
Atallah E; Nussenzveig R; Yin CC; Bueso-Ramos C; Tam C; Manshouri T; Pierce S; Kantarjian H; Verstovsek S
Leukemia; 2008 Jun; 22(6):1295-8. PubMed ID: 18059483
[No Abstract] [Full Text] [Related]
22. [Precursors of acute leukemia: myelodysplastic syndromes and myeloproliferative neoplasms].
Kreipe HH
Pathologe; 2011 Nov; 32 Suppl 2():271-6. PubMed ID: 22033685
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms.
Boiocchi L; Hasserjian RP; Pozdnyakova O; Wong WJ; Lennerz JK; Le LP; Dias-Santagata D; Iafrate AJ; Hobbs GS; Nardi V
Hum Pathol; 2019 Apr; 86():1-11. PubMed ID: 30594750
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders].
Remacha AF; Puget G; Nomdedéu JF; Estivill C; Sardà MP; Canals C
Med Clin (Barc); 2006 Oct; 127(16):601-4. PubMed ID: 17145024
[TBL] [Abstract][Full Text] [Related]
25. Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.
Aqil B; Sukhanova M; Behdad A; Jennings L; Lu X; Chen Q; Chen YH; Gao J
Hum Pathol; 2022 Nov; 129():81-89. PubMed ID: 36087739
[TBL] [Abstract][Full Text] [Related]
26. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1.
Ok CY; Trowell KT; Parker KG; Moser K; Weinberg OK; Rogers HJ; Reichard KK; George TI; Hsi ED; Bueso-Ramos CE; Tam W; Orazi A; Bagg A; Arber DA; Hasserjian RP; Wang SA
Mod Pathol; 2021 Jan; 34(1):20-31. PubMed ID: 32694616
[TBL] [Abstract][Full Text] [Related]
27. Molecular genetics of MDS/MPN overlap syndromes.
Hunter AM; Padron E
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101195. PubMed ID: 33038984
[TBL] [Abstract][Full Text] [Related]
28. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera.
Inano T; Araki M; Morishita S; Imai M; Yasuda H; Nitta H; Ito M; Edahiro Y; Ochiai T; Misawa K; Fukuda Y; Ohsaka A; Komatsu N
Br J Haematol; 2019 Oct; 187(1):e27-e31. PubMed ID: 31418453
[No Abstract] [Full Text] [Related]
29. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.
Wang SA; Hasserjian RP; Loew JM; Sechman EV; Jones D; Hao S; Liu Q; Zhao W; Mehdi M; Galili N; Woda B; Raza A
Leukemia; 2006 Sep; 20(9):1641-4. PubMed ID: 16871284
[No Abstract] [Full Text] [Related]
30. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
Szpurka H; Tiu R; Murugesan G; Aboudola S; Hsi ED; Theil KS; Sekeres MA; Maciejewski JP
Blood; 2006 Oct; 108(7):2173-81. PubMed ID: 16741247
[TBL] [Abstract][Full Text] [Related]
31. Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.
Machado-Neto JA; Traina F; Lazarini M; Campos Pde M; Pagnano KB; Lorand-Metze I; Costa FF; Saad ST
Clinics (Sao Paulo); 2011; 66(5):793-9. PubMed ID: 21789382
[TBL] [Abstract][Full Text] [Related]
32. MDS/MPN-RS-T justified inclusion as a unique disease entity?
Montalban-Bravo G; Garcia-Manero G
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101147. PubMed ID: 32460979
[TBL] [Abstract][Full Text] [Related]
33. Myelodysplastic/myeloproliferative neoplasms.
Hyjek E; Vardiman JW
Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
[TBL] [Abstract][Full Text] [Related]
34. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
Nangalia J; Massie CE; Baxter EJ; Nice FL; Gundem G; Wedge DC; Avezov E; Li J; Kollmann K; Kent DG; Aziz A; Godfrey AL; Hinton J; Martincorena I; Van Loo P; Jones AV; Guglielmelli P; Tarpey P; Harding HP; Fitzpatrick JD; Goudie CT; Ortmann CA; Loughran SJ; Raine K; Jones DR; Butler AP; Teague JW; O'Meara S; McLaren S; Bianchi M; Silber Y; Dimitropoulou D; Bloxham D; Mudie L; Maddison M; Robinson B; Keohane C; Maclean C; Hill K; Orchard K; Tauro S; Du MQ; Greaves M; Bowen D; Huntly BJP; Harrison CN; Cross NCP; Ron D; Vannucchi AM; Papaemmanuil E; Campbell PJ; Green AR
N Engl J Med; 2013 Dec; 369(25):2391-2405. PubMed ID: 24325359
[TBL] [Abstract][Full Text] [Related]
35. Suspected myelodysplastic/myeloproliferative neoplasm in a feline leukemia virus-negative cat.
Weeden AL; Taylor KR; Terrell SP; Gallagher AE; Wamsley HL
Vet Clin Pathol; 2016 Dec; 45(4):584-593. PubMed ID: 27870069
[TBL] [Abstract][Full Text] [Related]
36. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.
Steensma DP
J Mol Diagn; 2006 Sep; 8(4):397-411; quiz 526. PubMed ID: 16931578
[TBL] [Abstract][Full Text] [Related]
37. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
38. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
Zhang L; Dong H
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
[TBL] [Abstract][Full Text] [Related]
39. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
40. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.
Mangaonkar AA; Lasho TL; Ketterling RP; Reichard KK; Gangat N; Al-Kali A; Begna KH; Pardanani A; Al Ali NH; Talati C; Sallman D; Padron E; Patnaik MM; Tefferi A; Komrokji R
Blood Cancer J; 2022 Feb; 12(2):26. PubMed ID: 35105856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]